Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Each ingredient plays a specific role, and together they cover most of what your body needs to feel its best
For instance, in type 2 diabetes, GLP-1RAs improve glycemic control and reduce systemic inflammation
Molecular Identity Full Name Body Protection Compound 157 Structure Pentadecapeptide (15 amino acids) Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Weight ~1419 g/mol Origin Synthetic fragment derived from human gastric juice protein Mechanism of Action Published research identifies several pathways through which BPC-157 may affect tissue: Angiogenesis promotion: Studies show BPC-157 promotes blood vessel formation in animal models (Seiwerth et al., 2018) Nitric oxide system modulation: Interactions with NO pathways have been documented Growth factor activity: Research indicates effects on VEGF and EGF pathways FAK-paxillin pathway: Cell migration studies show activation of focal adhesion kinase Published Research Study Focus Model Publication Seiwerth et al
Hers takes the FDA-approved brand-name GLP-1 medication approach, while Willow focuses on non FDA-approved, personalized compounded GLP-1 medications
Moreover, we cannot attribute the anti-tumor effect of non-selective c-Met inhibitors to the inhibition of c-Met
The GLP-1 agonist comparison table below highlights some of the key differences between these agents
